Highbridge Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Highbridge Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300,000	Closed	-$549K	–	264
2024 Q4	$549K	Buy	+300,000	New	+$1.33M	0.02%	138
2016 Q3	–	Sell	-1,020	Closed	-$113K	–	1477
2016 Q2	$113K	Buy	+1,020	New	+$124K	﹤0.01%	1299
2015 Q4	–	Sell	-15,363	Closed	-$1.06M	–	1629
2015 Q3	$1.06M	Buy	+15,363	New	+$1.34M	0.02%	752
2015 Q1	–	Sell	-3,113	Closed	-$343K	–	1482
2014 Q4	$343K	Sell	3,113 -1,830	-37%	-$224K	﹤0.01%	926
2014 Q3	$584K	Buy	+4,943	New	+$616K	0.01%	818

Other funds holding INO

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Highbridge Capital Management's INO Position: Q1 2025 in Review

Highbridge Capital Management sold out of Inovio Pharmaceuticals (INO) in Q1 2025, closing a stake of 300,000 shares — an estimated $549K sold.

Highbridge Capital Management first reported a position in INO in Q3 2014 and held it in 5 quarters. The position peaked at $1.06M in Q3 2015. 107 funds tracked by Wall St. Rank hold INO as of Q1 2025.

Highbridge Capital Management reported no remaining Inovio Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Highbridge Capital Management sold 300,000 Inovio Pharmaceuticals shares in Q1 2025, an estimated $549K.
Highbridge Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 5 quarters.
Highbridge Capital Management's Inovio Pharmaceuticals position peaked at $1.06M in Q3 2015.
107 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2025.

Based on Highbridge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.